Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
SP-0125 by Sanofi for Respiratory Syncytial Virus (RSV) Infections: Likelihood of Approval
SP-0125 is under clinical development by Sanofi and currently in Phase III for Respiratory Syncytial Virus (RSV) Infections. According to...